SCHEMBL18129684

SCHEMBL18129684

COc1ccc(-c2cnc3[nH]cc(C4=CCN(C(=O)NC(C)C)CC4)c3c2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 3/20 0.61
CDK2 P24941 3/20 0.61
CHEK1 O14757 2/20 0.61
MAP4K4 O95819 2/20 0.61
CHEK2 O96017 2/20 0.61
PRKCG P05129 2/20 0.61
CDK1 P06493 2/20 0.61
PIM1 P11309 2/20 0.61
FGFR1 P11362 2/20 0.61
PRKACA P17612 2/20 0.61
RPS6KB1 P23443 2/20 0.61
MARK3 P27448 2/20 0.61
MAPK1 P28482 2/20 0.61
FLT4 P35916 2/20 0.61
FLT3 P36888 2/20 0.61
CLK2 P49760 2/20 0.61
GSK3A P49840 2/20 0.61
GSK3B P49841 2/20 0.61
IRAK1 P51617 2/20 0.61
RPS6KA3 P51812 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18129490 0.91 CHEK1 (0.53) DYRK1ACDK2CHEK1MAP4K4CHEK2
SCHEMBL18129636 0.91 CHEK1 (0.67) DYRK1ACDK2CHEK1MAP4K4CHEK2
SCHEMBL18129508 0.90 DYRK1A (0.55) DYRK1ACDK2CHEK1MAP4K4CHEK2
SCHEMBL18129499 0.90 CCNT1 (0.54) DYRK1ACDK2CHEK1MAP4K4CHEK2
SCHEMBL18129598 0.89 AXL (0.56) DYRK1ACDK2CHEK1MAP4K4CHEK2
SCHEMBL18129529 0.87 DYRK1A (0.55) DYRK1ACDK2CHEK1MAP4K4CHEK2
SCHEMBL18129664 0.87 CHEK1 (0.49) DYRK1ACDK2CHEK1MAP4K4CHEK2
SCHEMBL18129461 0.85 MAP3K11 (0.58) DYRK1ACDK2CHEK1MAP4K4CHEK2
SCHEMBL18129559 0.84 CDK2 (0.55) DYRK1ACDK2CHEK1MAP4K4CHEK2
SCHEMBL18129509 0.84 MAP3K11 (0.52) DYRK1ACDK2CHEK1MAP4K4CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10239873-B2 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2019-03-26 US claimed
US-20160297815-A1 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-13 US claimed
US-10239873-B2 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2019-03-26 US disclosed
US-10239873-B2 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2019-03-26 US disclosed
US-20160297815-A1 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-13 US disclosed
US-20160297815-A1 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297815-A1 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME TANK, NFKBIA, TBK1 DYRK1A 1134/4885CDK2 373/4885CHEK1 121/4885
US-10239873-B2 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same NFKBIA, TANK, TBK1 DYRK1A 1148/4885CDK2 377/4885CHEK1 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.